ImmunityBio
IBRX
104 hedge funds and large institutions have $155M invested in ImmunityBio in 2020 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 23 reducing their positions, and 21 closing their positions.
121% more capital invested
Capital invested by funds: $70.4M → $155M (+$85M)
48% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 21
39% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 23
9% more funds holding
Funds holding: 95 → 104 (+9)
1.31% more ownership
Funds ownership: 9.43% → 10.75% (+1.3%)
59% less call options, than puts
Call options by funds: $9.93M | Put options by funds: $24.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$3.31M |
| 3 |
JP Morgan Chase
New York
|
+$2.97M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.55M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$4.28M |
| 2 |
Two Sigma Advisers
New York
|
-$2.98M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.94M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$977K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$873K |
IBRX Hedge Fund Activity: Q4 2020 in Review
104 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2020, worth a combined $155M — up 121% from $70.4M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new IBRX positions and 21 closed out — a net gain of 10 holders — while 32 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock, adding an estimated $11.5M. The largest seller was Two Sigma Investments, exiting entirely with an estimated $4.28M sold.
- 104 institutional investors held ImmunityBio (IBRX) as of Q4 2020, up from 95 in Q3 2020.
- Funds reported $155M of ImmunityBio stock for Q4 2020, up 121% quarter-over-quarter.
- 31 funds opened new ImmunityBio positions in Q4 2020 and 21 closed out, a net change of +10 holders.
- The largest ImmunityBio buyer in Q4 2020 was BlackRock, an estimated $11.5M added.
- The largest ImmunityBio seller in Q4 2020 was Two Sigma Investments, an estimated $4.28M sold.
Based on aggregated 13F filings for Q4 2020.